Surface Oncology (SURF) – Analyst Comments
-
Positive Combo Data at ESMO Offers Positive Readthroughs to Surface Oncology (SURF) Adenosine Pathway Assets - BTIG
-
UPDATE: BTIG Starts Surface Oncology (SURF) at Buy
-
-
-
-
Back to SURF Stock Lookup